How long has tirzepatide been studied, and what does that research mean for you?

When did the serious clinical research on tirzepatide begin?

The earliest phase 1 studies of tirzepatide, testing its safety and tolerability in humans, date to around 2017. Phase 2 dose-finding work followed, and by 2020 Eli Lilly had launched the SURPASS programme, a large suite of trials in type 2 diabetes covering thousands of participants across different backgrounds, existing medications and health profiles. That diabetes research mattered for weight medicine: it established the drug's safety signals, its GI side-effect profile and its effect on body weight before the dedicated weight-management programme even began.

The SURMOUNT programme, aimed specifically at adults with obesity or overweight, started enrolling in late 2020. SURMOUNT-1 completed in 2022 and reported an average body-weight reduction of around 20–21% at the 15mg dose over 72 weeks, findings that NICE cited directly in its December 2024 appraisal (TA1026) when recommending tirzepatide for NHS weight management. That timeline from first human trial to national regulator approval is roughly seven years, which is broadly typical for a novel medicine in this class, and if you want to understand how long Mounjaro has been used both in trials and in practice, that question has its own dedicated page.

One common assumption is that tirzepatide is a very new medicine with limited data behind it. The fuller picture is more reassuring: by the time it received its UK weight-management licence, the clinical programme had generated a substantial body of peer-reviewed evidence across both diabetes and obesity indications.

How does the duration of study compare with the question of long-term safety?

This is the question most people are actually asking when they wonder how long the research has run. It is a fair one. The longest individual SURMOUNT trials followed participants for 72 weeks, just under a year and a half. That gives good visibility of side effects that emerge during titration and at maintenance dose, but it does not settle questions about effects over five or ten years.

What we do know from the combined SURPASS and SURMOUNT data is that the side-effect profile is consistent and dominated by gastrointestinal symptoms (nausea, changes in bowel habit, reduced appetite) most of which are most noticeable at the start of treatment or after a dose increase, then settle for many people. Serious adverse events were rare in the trials. The medicine carries a Black Triangle (▼) designation in the UK, meaning the MHRA continues to collect additional safety data on an ongoing basis; that is standard for newer medicines, not a signal that something is wrong. If you want to explore how long treatment is typically continued, that question has its own dedicated page.

For context on how quickly effects typically appear once treatment starts, the timeline from first dose to meaningful weight change is a separate question from the duration of the research, and worth looking at on its own terms.

What did the head-to-head trial add to the picture?

SURMOUNT-5 is significant because it addressed a gap the earlier trials left open: how does tirzepatide compare directly with the best-established alternative? The trial enrolled 751 adults with obesity but without diabetes, ran for 72 weeks, and compared tirzepatide at the highest tolerated dose against semaglutide 2.4mg. Tirzepatide produced greater average weight reduction across the group. NICE noted in its TA1026 committee discussions that indirect comparisons in the evidence base favour tirzepatide, and SURMOUNT-5 added a direct comparison to support that picture.

Knowing this matters when reading about the two medicines side by side. The evidence base for tirzepatide in weight management is now large enough to support cross-medicine comparisons, not just placebo-controlled estimates. For a fuller look at what Mounjaro is and how it works, our medicine overview covers the mechanism and licensed uses in plain language.

None of this tells you whether tirzepatide is right for you personally. A prescriber reviews your health history, current medicines and BMI before any prescription is written, that clinical step is the part no trial data can replace. If you're thinking about cost alongside all of this, our Mounjaro pricing page sets out what private treatment typically involves.

What does NICE's appraisal tell us about the overall evidence quality?

NICE appraisals are methodologically demanding. The committee reviewed the SURMOUNT data, considered indirect comparisons with other weight-loss medicines, examined cost-effectiveness models and scrutinised the quality of the trials before publishing TA1026 in December 2024. The fact that NICE recommended tirzepatide (and did so relatively quickly after its UK licence) reflects confidence in the robustness of the research rather than speed at the expense of rigour.

The recommendation covers adults with a BMI of 35 or above plus at least one weight-related comorbidity on the NHS, with lower thresholds applying for some ethnic backgrounds. But the clinical evidence base that underpins that recommendation is available to anyone considering the medicine privately, too. You can read the full NICE appraisal of tirzepatide to see exactly how the committee weighed the trial data. For a fuller picture of how long the medicine has been in use in practice (not just in trials) the real-world usage timeline adds useful context alongside the trial history. And if you have questions about your own situation, our clinical team is always a good place to start, you can find out more about who we are and how our prescribers work before you begin.

When you're ready to take the next step, start your free consultation and a GPhC-registered prescriber will review your details the same day.